Reports Q1 revenue $4.13M, consensus $7.96M. “We are excited about the transformative potential of our AI-driven metagenomi (MGX)cs platform across multiple indications in our pipeline,” said Brian C. Thomas, PhD, CEO and founder of Metagenomi. “For our lead program in hemophilia A, we are encouraged by the additional durability of response data demonstrating sustained FVIII activity at therapeutically relevant levels throughout our completed study of approximately 19 months in NHPs. Looking ahead, we plan to leverage these findings to inform the strategy for our MGX-001 program moving forward. Further, we remain well capitalized with cash runway anticipated to support our operations through key milestones into 2027.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGX:
- Metagenomi price target lowered to $7 from $14 at H.C. Wainwright
- Biotech stocks slide as Marks resignation seen being negative for sector
- BMO says Peter Marks resignation ‘significant negative’ for biotech
- Metagenomi Faces Legal Battle Over Alleged Misleading Statements in Moderna Collaboration
- Metagenomi, Inc. Reports 2024 Financial Results and Pipeline Progress